Liver-side of inflammatory bowel diseases: Hepatobiliary and drug-induced disorders

doi:10.4254/wjh.v13.i12.1828

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 13, Issue 12

This Article

Academic Content and Language Evaluation of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (9042)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-1) series, Tables (1-2) series.

Item

Count

PDF

1094

WORD

218

HTML

6098

Figures (1-1)

291

Tables (1-2)

235

Sum=7936

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

393

Download

713

Sum=1106

Dec 27, 2021 (publication date) through Nov 4, 2024

Times Cited of This Article

Times Cited (9)

Journal Information of This Article

Publication Name

World Journal of Hepatology

ISSN

1948-5182

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

World J Hepatol. Dec 27, 2021; 13(12): 1828-1849
Published online Dec 27, 2021. doi: 10.4254/wjh.v13.i12.1828

Liver-side of inflammatory bowel diseases: Hepatobiliary and drug-induced disorders

Stefano Mazza, Sara Soro, Maria Chiara Verga, Biagio Elvo, Francesca Ferretti, Fabrizio Cereatti, Andrea Drago, Roberto Grassia

Stefano Mazza, Sara Soro, Maria Chiara Verga, Biagio Elvo, Fabrizio Cereatti, Andrea Drago, Roberto Grassia, Gastroenterology and Digestive Endoscopy Unit, ASST Cremona, Cremona 26100, Italy

Francesca Ferretti, Gastroenterology Unit, ASST Fatebenefratelli-Sacco, Department of Biomedical and Clinical Sciences (DIBIC), Università degli Studi di Milano, Milan 20157, Italy

Author contributions: All authors contributed to literature search and data collect; Mazza S, Soro S and Elvo B wrote the paper; Verga MC, Ferretti F, Cereatti F, Drago A and Grassia R critically revised the paper and contributed to the final version of the manuscript.

Conflict-of-interest statement: Authors declare no conflict of interests for this article.

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/

Corresponding author: Stefano Mazza, MD, Doctor, Gastroenterology and Digestive Endoscopy Unit, ASST Cremona, Viale Concordia 1, Cremona 26100, Italy. stem311089@gmail.com

Received: March 1, 2021
Peer-review started: March 1, 2021
First decision: July 6, 2021
Revised: July 16, 2021
Accepted: November 13, 2021
Article in press: November 13, 2021
Published online: December 27, 2021
Processing time: 300 Days and 7 Hours

Core Tip

Core Tip: Hepatobiliary disorders are commonly associated with inflammatory bowel diseases (IBD) and represent a management challenge. They include (1) Immune-mediated diseases that can coexist with IBD, mainly primary sclerosing cholangitis; (2) Other non-immune-mediated disorders like gallstone disease; (3) Liver injury induced by drugs used in IBD; and (4) Risks related to concomitant viral hepatitis B and C. All these conditions are summarized in this review, according to the latest literature evidence and the current clinical practice guidelines.